日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

A Phase 2 Randomized Trial of NBI-1065846 (TAK-041) in Patients With Anhedonia Associated With Major Depressive Disorder: Results of the TERPSIS Study

NBI-1065846 (TAK-041) 治疗伴有重度抑郁症的快感缺失患者的 II 期随机试验:TERPSIS 研究结果

Benedetto, Shannon R; Ionescu, Adrian; Ge, Tingting; Furey, Maura; Lin, Swan; Jha, Manish K; Krystal, Andrew; Shah, Asim A; Walling, David P; Shah, Neel; Rizvi, Sakina J; Kennedy, Sidney; Laurenza, Antonio; Murthy, Venkatesha; Roberts, Eiry; Singh, Jaskaran B

Adverse Events and Measurement of Dissociation After the First Dose of Esketamine in Patients With TRD

难治性抑郁症患者首次服用艾司氯胺酮后不良事件及分离症状的测量。

Williamson, David; Turkoz, Ibrahim; Wajs, Ewa; Singh, Jaskaran B; Borentain, Stephane; Drevets, Wayne C

The effect of esketamine in patients with treatment-resistant depression with and without comorbid anxiety symptoms or disorder

艾司氯胺酮对伴或不伴有焦虑症状或障碍的难治性抑郁症患者的疗效

Daly, Ella J; Turkoz, Ibrahim; Salvadore, Giacomo; Fedgchin, Maggie; Ionescu, Dawn F; Starr, H Lynn; Borentain, Stephane; Trivedi, Madhukar H; Thase, Michael E; Singh, Jaskaran B

Cardiac Safety of Esketamine Nasal Spray in Treatment-Resistant Depression: Results from the Clinical Development Program

艾司氯胺酮鼻喷雾剂治疗难治性抑郁症的心脏安全性:临床开发项目的结果

Doherty, Teodora; Wajs, Ewa; Melkote, Rama; Miller, Janice; Singh, Jaskaran B; Weber, Michael A

Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial

艾司氯胺酮鼻喷雾剂联合口服抗抑郁药治疗对难治性抑郁症患者复发预防的疗效:一项随机临床试验

Daly, Ella J; Trivedi, Madhukar H; Janik, Adam; Li, Honglan; Zhang, Yun; Li, Xiang; Lane, Rosanne; Lim, Pilar; Duca, Anna R; Hough, David; Thase, Michael E; Zajecka, John; Winokur, Andrew; Divacka, Ilona; Fagiolini, Andrea; Cubala, Wieslaw J; Bitter, István; Blier, Pierre; Shelton, Richard C; Molero, Patricio; Manji, Husseini; Drevets, Wayne C; Singh, Jaskaran B

Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1)

固定剂量艾司氯胺酮鼻喷雾剂联合新型口服抗抑郁药治疗难治性抑郁症的疗效和安全性:一项随机、双盲、活性对照研究(TRANSFORM-1)的结果

Fedgchin, Maggie; Trivedi, Madhukar; Daly, Ella J; Melkote, Rama; Lane, Rosanne; Lim, Pilar; Vitagliano, Dawn; Blier, Pierre; Fava, Maurizio; Liebowitz, Michael; Ravindran, Arun; Gaillard, Raphael; Ameele, Hans Van Den; Preskorn, Sheldon; Manji, Husseini; Hough, David; Drevets, Wayne C; Singh, Jaskaran B

Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial

鼻内注射艾司氯胺酮辅助口服抗抑郁药治疗难治性抑郁症的疗效和安全性:一项随机临床试验

Daly, Ella J; Singh, Jaskaran B; Fedgchin, Maggie; Cooper, Kimberly; Lim, Pilar; Shelton, Richard C; Thase, Michael E; Winokur, Andrew; Van Nueten, Luc; Manji, Husseini; Drevets, Wayne C

Ketamine as a fast acting antidepressant: current knowledge and open questions

氯胺酮作为一种速效抗抑郁药:现有知识和未解决的问题

Salvadore, Giacomo; Singh, Jaskaran B

Neural circuitry and neuroplasticity in mood disorders: insights for novel therapeutic targets

情绪障碍中的神经回路和神经可塑性:为新的治疗靶点提供启示

Carlson, Paul J; Singh, Jaskaran B; Zarate, Carlos A Jr; Drevets, Wayne C; Manji, Husseini K